|  |  |  |  |
| --- | --- | --- | --- |
| ***Cohort 3*** | | | |
|  | **Combination ipilimumab and nivolumab -related colitis**  **(IN-COL)** | **Combination ipilimumab and nivolumab treated**  **with nil adverse events**  **(IN-NAE)** | **p value** |
| ***Number (N)*** | 14 | 12 | N/A |
| ***Age, median years (inter-quartile range)*** | 62 (47-70) | 59 (57-69) | 0.59 |
| ***Sex (N and % Male)*** | 11(71) | 4(44) | 0.38 |
| ***Melanoma Stage (AJCC v8; N)***  ***M1a***  ***M1b***  ***M1c***  ***M1d***  ***(Data not recorded)*** | 4  2  8  0  *(0)* | \*  a 5  b 3  c 1  d 0  *(3)* | 0.11 |
| ***Visceral Metastases (%)*** | 75 | 50 | 0.33 |
| ***Serum lactate dehydrogenase (LDH) median U/L (interquartile range)*** | 283 (209-618) | 329 (272-351) | 0.77 |
| ***Colitis treatment (N and %)***  ***IV Methylprednisone***  ***Infliximab***  ***Vedolizumab***  ***Colectomy*** | 7 (50)  6 (43)  0  0 | N/A | N/A |
| ***Histopathological features***  ***Mild inflammation***  ***Focal acute cryptitis***  ***Moderate colitis***  ***Moderate to severe inflammation***  ***Focal active proctitis***  ***Chronic colitis***  ***(Data not available)*** | 4  2  1  1  1  1  *(4)* | N/A | N/A |

**Table III: Clinical characteristics of Cohort 3 IN-C and IN-NAE groups.**